

(Under Corporate Insolvency Resolution Process)

November 8, 2019

**National Stock Exchange of India Ltd**  
**Listing Department**  
**Exchange Plaza, 5<sup>th</sup> Floor, Plot No: C/1**  
**G - Block, Bandra - Kurla Complex**  
**Bandra (East)**  
**Mumbai - 400 051.**

**BSE Limited**  
**Corporate Relationship Department**  
**1st floor, New Trading Ring**  
**Rotunda Building, P J Towers**  
**Dalal Street, Fort**  
**Mumbai - 400 001**

**Sub: Notification as per Listing Regulations – Unaudited Financial Results for the Quarter ended**  
**September 30, 2019**

Dear Sir/Madam

We had in our earlier communications informed that Corporate Insolvency Resolution Process (CIRP) has been initiated for "Orchid Pharma Limited" (the Company) under the provisions of the Insolvency and Bankruptcy Code, 2016 ('Code') vide an order of the Honourable National Company Law Tribunal with effect from 17 August, 2017. Pursuant to the initiation of the CIRP, the Powers of the Board of Directors of the Company stands suspended and the management of the affairs of the Company is vested with the Resolution Professional.

Pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Resolution Professional shall hold a Meeting on Thursday, November 14, 2019, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2019.

Kindly take the above on your records.

Thanking you,

Yours faithfully,



Mani S  
President –API, CSR&SH&E